Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 69

1.

Aflibercept-related sterile inflammation.

Hahn P, Kim JE, Stinnett S, Chung MM, Dugel PU, Flynn HW Jr, Huang SS, Sadda SR, Mahmoud TH; American Society of Retina Specialists Therapeutic Surveillance Committee..

Ophthalmology. 2013 May;120(5):1100-101.e1-5. doi: 10.1016/j.ophtha.2012.11.018. No abstract available.

PMID:
23642742
2.

Delayed onset panuveitis following intravitreal aflibercept injection.

Glading JA, Lake SR, Craig JE, Supramaniam D.

BMJ Case Rep. 2014 Jun 11;2014. pii: bcr2013202515. doi: 10.1136/bcr-2013-202515.

3.

Postmarketing analysis of aflibercept-related sterile intraocular inflammation.

Hahn P, Chung MM, Flynn HW Jr, Huang SS, Kim JE, Mahmoud TH, Sadda SR, Dugel PU.

JAMA Ophthalmol. 2015 Apr;133(4):421-6. doi: 10.1001/jamaophthalmol.2014.5650.

PMID:
25590968
4.

Anti-Vascular Endothelial Growth Factor Injections and Intraocular Pressure Measurement: Should We Throw the Baby out with the Bath Water?

Jampel H, Kalenak J.

Ophthalmology. 2015 Sep;122(9):1735-6. doi: 10.1016/j.ophtha.2015.05.030. No abstract available.

PMID:
26299718
5.

A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors.

Wang-Gillam A, Tew WP, Rothenberg ML, Dupont J, Cooper W, Sternas L, Buzenet G, Sosman JA, Spriggs DR, Lockhart AC.

Invest New Drugs. 2012 Oct;30(5):1958-61. doi: 10.1007/s10637-011-9753-y.

6.

Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study.

Brown DM, Heier JS, Clark WL, Boyer DS, Vitti R, Berliner AJ, Zeitz O, Sandbrink R, Zhu X, Haller JA.

Am J Ophthalmol. 2013 Mar;155(3):429-437.e7. doi: 10.1016/j.ajo.2012.09.026.

PMID:
23218699
7.

Aflibercept for age-related macular degeneration: a game-changer or quiet addition?

Browning DJ, Kaiser PK, Rosenfeld PJ, Stewart MW.

Am J Ophthalmol. 2012 Aug;154(2):222-6. doi: 10.1016/j.ajo.2012.04.020. Review.

PMID:
22813448
8.

Aflibercept for the treatment of neovascular age-related macular degeneration.

Verner-Cole EA, Davis SJ, Lauer AK.

Drugs Today (Barc). 2012 May;48(5):317-29. doi: 10.1358/dot.2012.48.5.1805931. Review.

PMID:
22645720
9.

Long-term follow-up of vascular endothelial growth factor inhibitor therapy for neovascular age-related macular degeneration.

Scott AW, Bressler SB.

Curr Opin Ophthalmol. 2013 May;24(3):190-6. doi: 10.1097/ICU.0b013e32835fefee. Review.

PMID:
23492430
10.

Neovascular age-related macular degeneration: individualizing therapy in the era of anti-angiogenic treatments.

Heier JS.

Ophthalmology. 2013 May;120(5 Suppl):S23-5. doi: 10.1016/j.ophtha.2013.01.059.

PMID:
23642783
11.

Intraocular inflammation following intravitreal injection of bevacizumab.

Bakri SJ, Larson TA, Edwards AO.

Graefes Arch Clin Exp Ophthalmol. 2008 May;246(5):779-81. doi: 10.1007/s00417-007-0754-7.

PMID:
18204851
12.

[Safety aspect of age macular degeneration treatment].

Zyrianov SK, Belousov IuB.

Vestn Oftalmol. 2012 Jul-Aug;128(4):75-7. Review. Russian. No abstract available.

PMID:
22994114
13.

Aflibercept (eylea) for age-related macular degeneration.

[No authors listed]

Med Lett Drugs Ther. 2012 Feb 6;54(1383):9-10. Review. No abstract available.

PMID:
22354219
14.

Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration.

Wickremasinghe SS, Michalova K, Gilhotra J, Guymer RH, Harper CA, Wong TY, Qureshi S.

Ophthalmology. 2008 Nov;115(11):1911-5. doi: 10.1016/j.ophtha.2008.05.007.

PMID:
18672291
15.

Treatment-related mortality with aflibercept in cancer patients.

Tabernero J, Hitier S, Derobert E, Van Cutsem E.

Eur J Clin Pharmacol. 2014 Oct;70(10):1269-70. doi: 10.1007/s00228-014-1715-9. No abstract available.

16.

Fever after intravitreal anti-VEGF injections.

Ladas ID, Kotsolis AI.

Graefes Arch Clin Exp Ophthalmol. 2010 Feb;248(2):295-6. doi: 10.1007/s00417-009-1171-x. No abstract available.

PMID:
19701644
17.

Vascular events in patients with age-related macular degeneration treated with intraocular bevacizumab.

Sheybani A, Kymes S, Schlief S, Apte R.

Retina. 2009 Nov-Dec;29(10):1404-8. doi: 10.1097/IAE.0b013e3181b32d13.

PMID:
19898178
18.

Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancer.

Tang PA, Cohen SJ, Kollmannsberger C, Bjarnason G, Virik K, MacKenzie MJ, Lourenco L, Wang L, Chen A, Moore MJ.

Clin Cancer Res. 2012 Nov 1;18(21):6023-31. doi: 10.1158/1078-0432.CCR-11-3252.

19.

Ranibizumab for neovascular age-related macular degeneration.

Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY; MARINA Study Group..

N Engl J Med. 2006 Oct 5;355(14):1419-31.

20.

Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES).

Wu L, Martínez-Castellanos MA, Quiroz-Mercado H, Arevalo JF, Berrocal MH, Farah ME, Maia M, Roca JA, Rodriguez FJ; Pan American Collaborative Retina Group (PACORES)..

Graefes Arch Clin Exp Ophthalmol. 2008 Jan;246(1):81-7.

PMID:
17674014

Supplemental Content

Support Center